Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. The companys lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells.

Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company targets hematologic as well as solid tumor indications and expects to initiate clinical studies next year.

Pi Therapeutics was founded based on technology in-licensed from Johns Hopkins University.